ArticleAnnals of the New York Academy of Sciences2009
An overview of cytokines and cytokine antagonists as therapeutic agents.
Article in Annals of the New York Academy of Sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis.Early intervention in psychiatry · 2026Article
- Delphinidin Exerts Immunomodulatory Effects in Canine Neutrophils and Peripheral Blood Mononuclear Cells by Limiting Tissue Damaging Mechanisms and Regulating Cytokine Responses.Animals : an open access journal from MDPI · 2026Article
- InCytokine, an Open-Source Software, Reveals a TREM2 Variant-Specific Cytokine Signature.International journal of molecular sciences · 2026Article
- An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and Beyond.The American journal of pathology · 2026Review
- Generating tolerance through in situ recruitment of regulatory T cells for allogeneic cell transplantation in a bioengineered lymphoid platform.Materials today. Bio · 2025Article
- Recombinant LAB vector engineered to secrete chicken IFN-λ3 induces an early but sustained activation of antiviral host responses against AIV infection.Poultry science · 2025Article
- Combined IFN-γ and TNF-α treatment enhances the susceptibility of breast cancer cells and spheroids to Natural Killer cell-mediated killing.Cell death & disease · 2025Article
- Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment.International journal of molecular sciences · 2025Article
- Mouse-Specific Single cell cytokine activity prediction and Estimation (MouSSE).PLoS computational biology · 2025Article
- Progress in brucellosis immune regulation inflammatory mechanisms and diagnostic advances.European journal of medical research · 2025Review
- Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment.Cells · 2025Review
- Redirecting immune signaling with cytokine adaptors.Nature communications · 2025Article
- The Role of Inflammation in the Pathogenesis of Comorbidity of Chronic Obstructive Pulmonary Disease and Pulmonary Tuberculosis.International journal of molecular sciences · 2025Review
- Chemokine ligand 2: beyond chemotaxis-a multifaceted role in tumor progression.Frontiers in immunology · 2025Review
- Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy.Current gene therapy · 2025Review
- A strategy to design protein-based antagonists against type I cytokine receptors.PLoS biology · 2024Article
- Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity.Nature immunology · 2024Article
- Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery.Advanced drug delivery reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cytokine-based therapies have the potential to provide novel treatments for cancer, autoimmune diseases, and many types of infectious disease. However, to date, the full clinical potential of cytokines as drugs has been limited by a number of factors. To discuss these limitations and explore ways to overcome them, the FDA partnered with the New York Academy of Sciences in March 2009 to host a two-day forum to discuss more effective ways to harness the clinical potential of cytokines and cytokine antagonists as therapeutic agents. The first day was focused primarily on the use of recombinant cytokines as therapeutic agents for treatment of human diseases. The second day focused largely on the use of cytokine antagonists as therapeutic agents for treatment of human diseases. This issue of the Annals includes more than a dozen papers that summarize much of the information that was presented during this very informative two-day conference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.